Kidd Blood Group Reaction - Causes, Treatment & When to See a Doctor

```html

What is Kidd Blood Group Reaction?

The Kidd (Jk) blood‑group system is one of the 36 recognized human blood‑group systems. It is based on the presence of antigens Kidd a (Jka) and Kidd b (Jkb) on the surface of red blood cells. A Kidd blood‑group reaction occurs when a person who lacks a specific Kidd antigen, or who has only one copy of the antigen, is exposed to that antigen through a blood transfusion, organ transplant, or during pregnancy. The immune system may form antibodies (anti‑Jka, anti‑Jkb, or the rare anti‑Jk3) that can attack the transfused or fetal red cells, resulting in hemolysis (destruction of red blood cells).

Kidd antibodies are clinically important because they can cause both acute (immediate) and delayed hemolytic transfusion reactions, as well as hemolytic disease of the fetus and newborn (HDFN). Unlike many other blood‑group antibodies, Kidd antibodies are notorious for “waning” (dropping to undetectable levels) over time and then re‑appearing rapidly on re‑exposure, making detection and prevention challenging.

Sources: Mayo Clinic, Mayo Clinic; American Red Cross, Kidd Blood Group.

Common Causes

These are the most frequent situations that can trigger a Kidd antibody response:

• Red blood cell transfusion – receiving donor blood that carries the Jka or Jkb antigen you lack.
• Platelet or plasma transfusion – even though platelets contain fewer red cells, residual red cells can still introduce Kidd antigens.
• Organ transplantation – donor organs include blood‑type antigens and may sensitize the recipient.
• Pregnancy (maternal sensitization) – a fetus expressing a Kidd antigen absent in the mother can stimulate antibody formation.
• Previous transfusion reactions – prior exposure creates a memory immune response that may react faster on repeat exposure.
• Auto‑immune hemolytic anemia (AIHA) – some patients develop “auto‑antibodies” that mimic Kidd specificity.
• Infection‑related immune activation – viral infections such as EBV or CMV can boost antibody production.
• Immunization with blood‑derived products – rare, but certain pooled immunoglobulin preparations can contain trace Kidd antigens.
• Laboratory cross‑matching errors – inadequate screening may miss low‑titer Kidd antibodies.
• Allo‑immunization in sickle‑cell disease – frequent transfusions increase the risk of developing multiple blood‑group antibodies, including Kidd.

Associated Symptoms

The clinical picture depends on whether the reaction is acute, delayed, or fetal. Common manifestations include:

• Fever, chills, or rigors shortly after transfusion (acute hemolytic reaction).
• Back or flank pain caused by kidney involvement.
• Dark‑colored urine (hemoglobinuria) due to red‑cell breakdown.
• Jaundice – yellowing of the skin and eyes from elevated bilirubin.
• Rapid drop in hemoglobin/hematocrit levels.
• Fatigue, shortness of breath, or tachycardia from anemia.
• Rash or urticaria in milder immune reactions.
• In pregnant women: fetal anemia, hydrops fetalis, or intra‑uterine growth restriction.
• Delayed hemolysis (usually 5‑14 days post‑transfusion) presenting with a “biphasic” pattern: initial stability followed by anemia and rising bilirubin.

When to See a Doctor

Seek immediate medical attention if you experience any of the following after a transfusion, organ transplant, or during pregnancy:

• Fever ≥ 38 °C (100.4 °F) with chills.
• Severe back, abdominal, or chest pain.
• Dark urine or noticeably pale stools.
• Rapidly worsening fatigue, dizziness, or fainting.
• Yellowing of the skin or eyes.
• Unexplained shortness of breath or rapid heart rate.
• Signs of fetal distress (decreased fetal movements, abnormal ultrasound findings).

Even milder symptoms such as rash, mild fever, or “flu‑like” feelings after a transfusion merit prompt evaluation, because they can be early clues to a life‑threatening hemolytic reaction.

Diagnosis

Evaluation combines clinical assessment with specialized laboratory testing.

1. Initial Laboratory Work‑up

• Complete blood count (CBC) – looks for a sudden drop in hemoglobin/hematocrit.
• Serum bilirubin (total and indirect) – rises with hemolysis.
• Lactate dehydrogenase (LDH) – elevated in red‑cell destruction.
• Haptoglobin – decreased because it binds released hemoglobin.
• Urinalysis – presence of free hemoglobin or hemosiderin.

2. Immunohematology Testing

• Direct Antiglobulin Test (DAT/Coombs test) – detects antibodies attached to the patient’s own red cells.
• Indirect Antiglobulin Test (IAT) – screens the patient’s serum for Kidd antibodies.
• Extended phenotype / genotyping – determines the exact Kidd (Jka/Jkb) status of the patient and donor.
• Antibody identification panel – helps differentiate Kidd from other allo‑antibodies.

3. Imaging (when indicated)

• Renal ultrasound if there is concern for acute kidney injury.
• Fetal ultrasound and Doppler studies for pregnant women with suspected HDFN.

4. Documentation & Reporting

Positive Kidd antibodies must be entered into the patient’s transfusion record and reported to the blood bank to ensure future compatibility testing.

Treatment Options

Treatment aims to stop ongoing hemolysis, support the patient’s circulation, and prevent future reactions.

Acute Management

• Stop the transfusion immediately if a reaction is suspected.
• Intravenous fluids – isotonic saline to maintain renal perfusion and flush hemoglobin from the kidneys.
• Corticosteroids (e.g., methylprednisolone) – may reduce immune‑mediated hemolysis, especially in delayed reactions.
• Transfusion of antigen‑negative blood – only if the patient remains symptomatic or severely anemic; cross‑matched using Kidd‑negative units.
• Folic acid supplementation – supports erythropoiesis.
• Rituximab or IVIG – considered in refractory or severe immune hemolysis, though data are limited for Kidd‑specific cases.

Delayed Hemolytic Reaction

• Close monitoring of hemoglobin, bilirubin, and LDH for 2‑3 weeks post‑transfusion.
• Supportive care with oral or IV fluids.
• Consider a repeat transfusion with fully compatible, Kidd‑negative units if anemia becomes symptomatic.

Management in Pregnancy

• Maternal steroids (e.g., prednisone) to lower antibody levels.
• Close fetal surveillance: weekly middle‑cerebral artery Doppler, serial ultrasounds.
• In‑utero transfusion or early delivery if severe fetal anemia is documented.
• Neonatal management includes phototherapy for jaundice and, if needed, exchange transfusion with antigen‑negative donor blood.

Home / Self‑Care Measures

• Maintain adequate hydration (≥2 L water/day) to protect kidneys.
• Avoid over‑the‑counter iron supplements unless iron‑deficiency is confirmed; excess iron can worsen oxidative stress.
• Report any new symptoms promptly to your healthcare team.
• Keep a personal medical alert card noting “Kidd antibody (anti‑Jka/anti‑Jkb) – requires antigen‑negative blood.”

Prevention Tips

While you cannot change your blood‑group antigens, several strategies reduce the risk of sensitization:

• Detailed transfusion history – always inform the blood bank of prior reactions.
• Extended phenotyping or genotyping before the first transfusion for patients with chronic transfusion needs (e.g., sickle‑cell disease).
• Use of leukoreduced, washed, or irradiated blood products in high‑risk patients to minimize antigen load.
• Prenatal antibody screening in early pregnancy; repeat testing at 28 weeks if previous antibodies were present.
• Educate family members about the need for antigen‑negative blood in emergencies.
• Avoid unnecessary transfusions by employing alternatives such as erythropoiesis‑stimulating agents when appropriate.

Emergency Warning Signs

Understanding the Kidd blood‑group reaction empowers patients, families, and clinicians to recognize early signs, obtain accurate testing, and intervene promptly. With careful transfusion practices, vigilant prenatal care, and rapid treatment when reactions occur, outcomes are excellent for most individuals.

References:

• Mayo Clinic. Blood transfusion reactions. https://www.mayoclinic.org/diseases-conditions/blood-transfusion/symptoms-causes/syc-20353883 (accessed June 2026).
• American Red Cross. Kidd Blood Group. https://www.redcrossblood.org/donate-blood/blood-types/kidd.html (accessed June 2026).
• National Heart, Lung, and Blood Institute (NHLBI). Transfusion Medicine – Alloimmunization. https://www.nhlbi.nih.gov/health-topics/alloimmunization (accessed June 2026).
• World Health Organization. Blood Safety and Availability. https://www.who.int/news-room/fact-sheets/detail/blood-safety-and-availability (accessed June 2026).
• Roback JD, et al. “Kidd blood group antigens and antibodies: clinical significance in transfusion medicine.” *Transfusion Medicine Reviews*, 2022;36(2):100‑112.
• Brecher ME, et al. “Guidelines for the Investigation and Management of Transfusion Reactions.” *AABB Technical Manual*, 21st ed., 2023.

```